Leonard Braden Michael's Form 4 filing
Aclaris Therapeutics, Inc. (ACRS) · filed Jun 13, 2024
- Accession no.
- 0001373604-24-000035
- Filed
- Jun 13, 2024
- Trade date
- Jun 11-13, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $1.78M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Leonard Braden MichaelCIK 0001373603 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 11, 2024 | Common Stock | PPurchaseAcquired | +1,000,000 | $1.08 | +$1,080,000 | 10,395,934 | Indirect | |
| Jun 12, 2024 | Common Stock | PPurchaseAcquired | +82,579 | $1.14 | +$94,140.06 | 10,478,513 | Indirect | |
| Jun 13, 2024 | Common Stock | PPurchaseAcquired | +28,621 | $1.14 | +$32,627.94 | 10,507,134 | Indirect | |
| Jun 13, 2024 | Common Stock | PPurchaseAcquired | +500,000 | $1.15 | +$575,000 | 11,007,134 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.